Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

Biochem/physiol Actions

SET and MYND domain containing 2 (SMYD2) might act as a putative oncogene by methylating p53 and reducing its tumor suppressive role. Overexpression of SMYD2 gene is associated with pathogenesis and metastasis of oesophageal cancer, squamous cell carcinoma (ESCC). Therefore, it is considered as a potent therapeutic target for ESCC. SMYD2 has capacity to catalyze the methylation of histone and non-histone substrates. AZ505 acts as a potent and selective inhibitor of SMYD2 and aids in the improvement of novel cancer treatment.

General description

SET and MYND domain containing 2 (SMYD2) is encoded by the gene mapped to human chromosome 1q32.3-q41. The encoded protein belongs to SMYD family of protein lysine methyltransferases.Human SMYD2 (GenBank Accession No. NM_020197), full length with N-terminal DDDDK tag (FLAG), MW = 49.7kDa, expressed in a Baculovirus infected Sf9 cell expression system.

Physical form

Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 100 µg/ml FLAG peptide, 20% glycerol and 3 mM DTT.

Preparation Note

Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.